| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.006 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.008 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | 0.43 | 0.009 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.009 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.092 | 0.01 |